© 2023 BioMarin. All rights reserved.

BioMarin to Hold Conference Call Today, May 16, at 12:00 PM EDT (18:00 CEST) to Discuss Recent Company Developments and First Quarter 2005 Financial Results
Call to be Broadcast Live Over the Internet
May 16, 2005
NOVATO, Calif.

BioMarin Pharmaceutical Inc. (Nasdaq and SWX: BMRN) today announced that the company will host a conference call today, Monday, May 16, 2005, at 12:00 p.m. EDT (18:00 CEST), to discuss recent company developments and financial results from the first quarter of 2005. The call will be broadcast live over the internet and available on the investor section of the BioMarin website, http://www.bmrn.com/.

   What:  BioMarin Conference Call to Discuss Recent Company Developments
          and First Quarter 2005 Financial Results

   Date:  Monday, May 16, 2005

   Time:  12:00 p.m. EDT (18:00 CEST)

   Dial in Numbers:

     U.S. & Canada Toll-free Dial in #: 800.299.9086
     International Dial in #: 617.786.2903
     Participant Code:  69323515
     Replay Toll-free Dial in #: 888.286.8010
     Replay International Dial in #: 617.801.6888
     Replay Code: 30154746

  Webcast:  Investor section of http://www.bmrn.com/

  About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company's product portfolio is comprised of two approved products, Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I) and Orapred(R) (prednisolone sodium phosphate oral solution) for severe asthma, and multiple investigational product candidates including rhASB (galsulfase), a BLA/MAA-stage product candidate under regulatory review for the treatment of mucopolysaccharidosis VI (MPS VI), and Phenoptin(TM) (sapropterin hydrochloride), a Phase 3 product candidate for the treatment of phenylketonuria (PKU). For additional information, please visit http://www.bmrn.com/. Information on BioMarin's website is not incorporated by reference into this press release.

Aldurazyme(R) is a registered trademark of BioMarin/Genzyme LLC.

Orapred(R) is a registered trademark of Medicis Pediatrics, Inc. and is used under license.


   Investors                           Media
   Joshua A. Grass                     Susan Ferris
   BioMarin Pharmaceutical Inc.        BioMarin Pharmaceutical Inc.
   (415) 506-6777                      (415) 506-6701

SOURCE: BioMarin Pharmaceutical Inc.

CONTACT: Investors: Joshua A. Grass, +1-415-506-6777, Media: Susan
Ferris, +1-415-506-6701, both of BioMarin Pharmaceutical Inc.